TP53 and cancer: As mutant p53 acquires pro-oncogenic activity and also contributes at least in part to drug resistance of aggressive cancers, we have sought to examine GEM sensitivity of p53-mutated human pancreatic cancer MiaPaCa-2 cells and p53-proficient human pancreatic cancer SW1990 cells.